Bausch Health Companies Inc. (NYSE:BHC) Given Average Rating of “Hold” by Brokerages

Bausch Health Companies Inc. (NYSE:BHC) has earned a consensus rating of “Hold” from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $7.33.

A number of equities analysts have recently commented on BHC shares. Raymond James assumed coverage on Bausch Health Companies in a research note on Wednesday, July 10th. They issued a “market perform” rating and a $8.00 price objective on the stock. Piper Sandler cut Bausch Health Companies from a “neutral” rating to an “underweight” rating and reduced their price objective for the company from $9.00 to $3.00 in a research report on Friday, August 2nd. Royal Bank of Canada dropped their price objective on shares of Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating on the stock in a report on Friday, August 2nd. StockNews.com lowered shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Truist Financial decreased their target price on Bausch Health Companies from $8.00 to $7.00 and set a “hold” rating on the stock in a research report on Thursday, July 25th.

Insider Transactions at Bausch Health Companies

In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $6.21, for a total transaction of $83,027.70. Following the sale, the executive vice president now owns 435,198 shares of the company’s stock, valued at approximately $2,702,579.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 8.12% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bausch Health Companies

Institutional investors have recently modified their holdings of the business. Salem Investment Counselors Inc. acquired a new stake in Bausch Health Companies during the 1st quarter worth $32,000. Principal Securities Inc. bought a new position in Bausch Health Companies during the fourth quarter worth about $31,000. Headlands Technologies LLC acquired a new position in shares of Bausch Health Companies during the 2nd quarter worth about $35,000. MQS Management LLC bought a new stake in shares of Bausch Health Companies in the 2nd quarter valued at about $71,000. Finally, Certuity LLC acquired a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $75,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Stock Performance

NYSE:BHC opened at $7.18 on Friday. The stock has a market cap of $2.59 billion, a price-to-earnings ratio of -5.79 and a beta of 0.75. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The business has a fifty day moving average of $6.24 and a 200-day moving average of $7.36.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 742.06%. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.33 billion. During the same period in the prior year, the company earned $0.81 EPS. On average, equities research analysts predict that Bausch Health Companies will post 3.61 EPS for the current year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.